Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonism to discontinue insulin in type 2 diabetes: a feasibility study

Duodenal mucosal resurfacing (DMR) is an endoscopic intervention in which the duodenal mucosa is ablated by hydrothermal energy. DMR improves glycemic control in patients with type 2 diabetes (T2D), most likely by altered duodenal signaling leading to insulin sensitization. We studied whether we cou...

Full description

Saved in:
Bibliographic Details
Published in:Gastrointestinal endoscopy 2021-07, Vol.94 (1), p.111-120.e3
Main Authors: van Baar, Annieke C.G., Meiring, Suzanne, Smeele, Paul, Vriend, Tessa, Holleman, Frits, Barlag, Marjon, Mostafavi, Nahid, Tijssen, Jan G.P., Soeters, Maarten R., Nieuwdorp, Max, Bergman, Jacques J.G. H.M.
Format: Article
Language:English
Subjects:
Blood Glucose
Diabetes Mellitus, Type 2 - drug therapy
Feasibility Studies
Glucagon-Like Peptide-1 Receptor
Glycated Hemoglobin A
Humans
Hypoglycemic Agents - therapeutic use
Insulin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Duodenal mucosal resurfacing (DMR) is an endoscopic intervention in which the duodenal mucosa is ablated by hydrothermal energy. DMR improves glycemic control in patients with type 2 diabetes (T2D), most likely by altered duodenal signaling leading to insulin sensitization. We studied whether we could discontinue insulin use in T2D patients by combining DMR with glucagon-like peptide-1 receptor agonist (GLP-1RA) and lifestyle counseling. In this single-arm, single-center feasibility study in 16 insulin-treated patients with T2D (hemoglobin A1c [HbA1c] ≤8.0%, basal insulin 
ISSN:0016-5107
1097-6779
DOI:10.1016/j.gie.2020.12.021